Yves Levy
18Patents
5h-index
22Co-inventors
66Inventor score
Filing activity: Sep 24, 1979 → Jun 19, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8518410B2 | Fusion protein with HIV antigen | Emerging Cross-Sectional Technologies | 40 | Active |
| US4275302A | Method and device for converting thermal images into secondary images, e. g. visible images | Physics | 39 | Expired |
| US8961991B2 | Anti-CD40 targeted fusion proteins | Emerging Cross-Sectional Technologies | 38 | Active |
| US9416186B2 | Antigen presenting cell targeted anti-viral vaccines | Emerging Cross-Sectional Technologies | 25 | Active |
| US9862927B2 | Dendritic cell vaccines | Chemistry; Metallurgy | 7 | Active |
| US10662253B2 | Antibodies against human CD39 and use thereof for inhibiting T regulatory cells activity | Emerging Cross-Sectional Technologies | 5 | Active |
| US7678584B2 | Method for characterizing a surface, and device therefor | Physics | 3 | Active |
| US9885017B2 | Compositions and methods to immunize against hepatitis C virus | Chemistry; Metallurgy | 1 | Active |
| US11685792B2 | Antibodies against human CD39 and use thereof for inhibiting T regulatory cells activity | Chemistry; Metallurgy | 1 | Active |
| US11219683B2 | Methods and compositions for treating and preventing HIV | Chemistry; Metallurgy | 0 | Active |
| US8932599B2 | Synthetic gene construct coding for an HIV1 GAG and use thereof for obtaining anti-HIV-1 vaccines | Chemistry; Metallurgy | 0 | Active |
| US10610585B2 | Methods and compositions for treating and preventing HIV | Chemistry; Metallurgy | 0 | Active |
| US10724095B2 | Diagnostic markers of immunosenescence and methods for determining the susceptibility to nosocomial infections | Physics | 0 | Active |
| US10722572B2 | Methods and compositions for treating and preventing HIV | Chemistry; Metallurgy | 0 | Active |
| US7998726B2 | Method for fixing a protein on a pyrrole-based polymer and use thereof for making a sensor | Physics | 0 | Expired |
| US9804172B2 | Soluble ST2 as a marker for risk of mortality in HIV-infected subjects | Physics | 0 | Active |
| US10988544B2 | Fusion proteins comprising an anti-CD40 antibody and HIV antigenic peptides | Emerging Cross-Sectional Technologies | 0 | Active |
| US10548980B2 | P2X7 receptor antagonists for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV) | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.